0001415889-24-016195.txt : 20240610
0001415889-24-016195.hdr.sgml : 20240610
20240610161516
ACCESSION NUMBER: 0001415889-24-016195
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240606
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOWEN MAXINE
CENTRAL INDEX KEY: 0001280044
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 241032887
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 701 LEE ROAD
STREET 2: SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 701 LEE ROAD
STREET 2: SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
form4-06102024_040609.xml
X0508
4
2024-06-06
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001280044
GOWEN MAXINE
C/O ACLARIS THERAPEUTICS, INC.
701 LEE ROAD, SUITE 103
WAYNE
PA
19087
true
false
false
false
0
Stock Option (Right to Buy)
1.03
2024-06-06
4
A
0
15750
0
A
2034-06-05
Common Stock
15750
15750
D
Restricted Stock Units
2024-06-06
4
A
0
4793
0
A
Common Stock
4793
4793
D
The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date.
This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date.
/s/ Matthew Rothman, Attorney-in-Fact
2024-06-10